<DOC>
	<DOCNO>NCT02569372</DOCNO>
	<brief_summary>This study SAD ( Single Ascending Dose ) /MAD ( Multiple Ascending Dose ) study Explore Tolerability , Safety Pharmacokinetics/Pharmacodynamics GC1102 ( Recombinant Hepatitis B Human Immunoglobulin ) Chronic Hepatitis B Patients .</brief_summary>
	<brief_title>A Phase 1 Study GC1102 ( Recombinant Hepatitis B Immunoglobulin ) Chronic Hepatitis B Patients</brief_title>
	<detailed_description>GC1102 new recombinant hepatitis B human immunoglobulin . This study compose 2 Parts , Part A SAD Part B MAD total 4 dose program escalate confirm safety . Maximum 48 subject participate study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients chronic hepatitis B diagnose chronic hepatitis B carrier give write informed consent . Patients age ≥19 ≤ 65 year If Naïve Nucleos ( ) ide analogs therapy , HBeAg ( ) , HBsAg 1,000 IU/mL less HBV DNA 2,000IU/mL less Or If currently receive Nucleos ( ) ide analogs therapy , HBeAg ( ± ) , HBsAg 1,000 IU/mL less HBV DNA ( : limit detection 60 IU/mL less ) . Patients currently involve participate clinical trial within 30 day . Patients coinfected HAV , HCV HIV Patients history malignant tumor within 5 year except basal cell carcinoma skin , cervical intraepithelial neoplasia . Patients active infection except chronic hepatitis infection . Patients liver disease complication gastroesophageal variceal , ascites hepatic encephalopathy . Having eGFR 59 mL/min/1.73m2 less MDRD Evaluation phase ( moderate reduction GFR ) Having blood protein 1+ urine analysis microscopic examination . Patients clinically significant kidney disease include glomerulonephritis , anuria , acute renal failure , dialysis renal transplantation . Patients Vasculitis . Having leukocytes &lt; 3.0 x109/L Having Absolute Neutrophil Count &lt; 1.5x109/L Having platelet &lt; 750,000/mm3 screen Having hemoglobin &lt; 10g/dL Having positive sign serum cryoglobulin level . Having serum antinuclear antibody ( ANA ) 1:160 Patients show positive sign serum perinuclear antiNeutrophil Cytoplasmic Antibodies ( pANCA ) . Patients show positive sign serum cytoplasmic antiNeutrophil Cytoplasmic Antibodies ( cANCA ) . Patients history suspect immune disease Patients experience cardiovascular attack , myocardiac infarction , heart failure , PTCA coronary artery bypass , angina , arrhythmia , clinically meaningful valvular heart disease , cerebral infarction cerebral hemorrhage within 6 month . Patients history anaphylaxis main component subcomponent study drug . Patients administer live vaccine parentally ( measles vaccine , parotitis vaccine , rubella vaccine , cholera combine vaccine , varicella vaccine ) within 3 month prior dose study drug . Patients receive immunosuppressant , immunitymodifying drug include interferon agent , cytotoxic chemotherapy affect immune system , radiation therapy within 3 month prior dose study drug Patients treat immunoglobulin within 3 month prior dose study drug Patients treat systemic steroid Therapy ( 20 mg/day prednisolone equivalence administer every day 14 day , 700 mg cumulative dose period time ) within 3 month prior dose study drug ( topical administration topical ointment , eye drop , inhalant intranasal use , intraarticular injection , tendon injection acceptable ; alternativeday treatment acceptable even though administer 14 day ) Women show positive sign pregnancy test administer study drug . Those agree use appropriate contraceptive method ( condom , diaphoretic , intrauterine device , oral contraceptive hormone , vasectomy male sex partner ) clinical trial . Those experienced bleed 400ml blood donation within 8 week prior dose study drug . Those abused alcohol drug within 6 month . Those judge disqualify join clinical trial investigator clinically significant medical psychiatric condition .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>